A pharmacokinetic study of intramuscular (IM) parecoxib sodium in normal subjects

Journal of Clinical Pharmacology

Volumn 41, Issue 10, 2001, Pages 1111-1119

  Karim, A ^a   Laurent, A ^a   Slater, M E ^a   Kuss, M E ^a   Qian, J ^a   Crosby Sessoms, S L ^a   Hubbard, R C ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; PARECOXIB; SC 66905; UNCLASSIFIED DRUG; VALDECOXIB; VALDECOXIB DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; ENZYME INHIBITION; HEADACHE; HEMATOMA; HUMAN; HUMAN EXPERIMENT; INJECTION PAIN; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TASTE AVERSION; VERTIGO; XEROSTOMIA;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; HUMANS; INJECTIONS, INTRAMUSCULAR; ISOXAZOLES; MALE; MIDDLE AGED; SULFONAMIDES;

EID: 0034829899     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700122012607     Document Type: Article

References (14)

1. Prostoglandins, arachidonic acid, and inflammation
2. The actions of NSAIDs
3. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
4. Ketorolac: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential
5. Parenteral ketorolac and risk of gastrointestinal and operative site bleeding: A postmarketing surveillance study
6. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase
7. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2-specific inhibitors
8. Selective inhibition of inducible cyclooxygenase-2 in vivo is antiinflammatory and nonulcerogenic
9. The classification of cyclooxygenase inhibitors
10. Cyclooxygenase in biology and disease
11. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease
12. 4-[5-Methyl-3-phenyfisoxazol-4-yll-benzenesulfonamide. Valdecoxib: A potent and selective inhibitor of COX-2
13. N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration
14. An endoscopic study of the gastroduodenal effects of SC-69124A, a parenteral COX-2-specific inhibitor, in the elderly